Loading...

Trevena

Nasdaq:TRVN
Snowflake Description

Excellent balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
TRVN
Nasdaq
$103M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of treatment options that target and treat diseases affecting the central nervous system. The last earnings update was 40 days ago. More info.


Add to Portfolio Compare Print
  • Trevena has significant price volatility in the past 3 months.
TRVN Share Price and Events
7 Day Returns
9.9%
NasdaqGS:TRVN
2.8%
US Biotechs
0.1%
US Market
1 Year Returns
-34.7%
NasdaqGS:TRVN
-5.6%
US Biotechs
1.2%
US Market
TRVN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Trevena (TRVN) 9.9% -15.3% -33.9% -34.7% -81.3% -74.4%
US Biotechs 2.8% 1.7% -6% -5.6% 14.4% 9.6%
US Market 0.1% 0.6% 0.9% 1.2% 36.7% 37.9%
1 Year Return vs Industry and Market
  • TRVN underperformed the Biotechs industry which returned -5.6% over the past year.
  • TRVN underperformed the Market in United States of America which returned 1.2% over the past year.
Price Volatility
TRVN
Industry
5yr Volatility vs Market
Related Companies

TRVN Value

 Is Trevena undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Trevena. This is due to cash flow or dividend data being unavailable. The share price is $1.11.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Trevena's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Trevena's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:TRVN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-0.34
NasdaqGS:TRVN Share Price ** NasdaqGS (2019-06-18) in USD $1.11
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 19.39x
United States of America Market PE Ratio Median Figure of 3,092 Publicly-Listed Companies 17.63x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Trevena.

NasdaqGS:TRVN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:TRVN Share Price ÷ EPS (both in USD)

= 1.11 ÷ -0.34

-3.28x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Trevena is loss making, we can't compare its value to the US Biotechs industry average.
  • Trevena is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Trevena's expected growth come at a high price?
Raw Data
NasdaqGS:TRVN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.28x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
21.2%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 1.11x
United States of America Market PEG Ratio Median Figure of 2,126 Publicly-Listed Companies 1.53x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Trevena, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Trevena's assets?
Raw Data
NasdaqGS:TRVN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $0.50
NasdaqGS:TRVN Share Price * NasdaqGS (2019-06-18) in USD $1.11
United States of America Biotechs Industry PB Ratio Median Figure of 425 Publicly-Listed Biotechs Companies 3.03x
United States of America Market PB Ratio Median Figure of 5,244 Publicly-Listed Companies 1.79x
NasdaqGS:TRVN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:TRVN Share Price ÷ Book Value per Share (both in USD)

= 1.11 ÷ 0.50

2.21x

* Primary Listing of Trevena.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Trevena is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Trevena's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Trevena has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

TRVN Future Performance

 How is Trevena expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
21.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Trevena expected to grow at an attractive rate?
  • Trevena's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Trevena's earnings growth is expected to exceed the United States of America market average.
  • Trevena's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:TRVN Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:TRVN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 21.2%
NasdaqGS:TRVN Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 56.7%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.9%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 18.3%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:TRVN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:TRVN Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 70 4 1
2022-12-31 43 -13 1
2021-12-31 22 -44 1
2020-12-31 9 -42 1
2019-12-31 0 -28 2
NasdaqGS:TRVN Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 6 -23 -27
2018-12-31 6 -25 -31
2018-09-30 6 -31 -38
2018-06-30 3 -39 -49
2018-03-31 -52 -60
2017-12-31 -71 -72
2017-09-30 0 -87 -93
2017-06-30 0 -100 -107
2017-03-31 2 -100 -106
2016-12-31 4 -92 -103
2016-09-30 6 -76 -82
2016-06-30 8 -63 -63

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Trevena's earnings are expected to grow significantly at over 20% yearly.
  • Trevena's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:TRVN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Trevena Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:TRVN Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.03 0.03 0.03 1.00
2022-12-31 -0.12 -0.12 -0.12 1.00
2021-12-31 -0.42 -0.42 -0.42 1.00
2020-12-31 -0.37 -0.32 -0.41 2.00
2019-12-31 -0.31 -0.25 -0.37 2.00
NasdaqGS:TRVN Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -0.34
2018-12-31 -0.42
2018-09-30 -0.55
2018-06-30 -0.76
2018-03-31 -0.98
2017-12-31 -1.21
2017-09-30 -1.63
2017-06-30 -1.94
2017-03-31 -1.97
2016-12-31 -1.97
2016-09-30 -1.59
2016-06-30 -1.27

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Trevena will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Trevena's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Trevena has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

TRVN Past Performance

  How has Trevena performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Trevena's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Trevena does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Trevena's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Trevena's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Trevena's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Trevena Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:TRVN Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 5.73 -26.93 16.83 13.38
2018-12-31 5.73 -30.78 18.84 15.82
2018-09-30 5.50 -37.53 20.05 -28.70
2018-06-30 2.50 -49.04 21.37
2018-03-31 -60.17 19.83 53.57
2017-12-31 -71.87 19.64 48.97
2017-09-30 0.00 -93.25 18.88 41.78
2017-06-30 0.00 -107.15 17.73
2017-03-31 1.88 -105.93 17.04
2016-12-31 3.75 -102.99 16.08 89.96
2016-09-30 5.63 -82.36 15.51
2016-06-30 7.50 -63.07 14.22
2016-03-31 7.50 -55.38 13.63
2015-12-31 6.25 -50.53 12.80
2015-09-30 4.38 -48.36 11.35
2015-06-30 2.50 -53.28 11.10
2015-03-31 0.63 -53.26 10.47
2014-12-31 -49.73 9.40
2014-09-30 0.00 -43.42 8.91
2014-06-30 0.00 -36.76 7.58
2014-03-31 0.09 -30.02 5.98
2013-12-31 0.13 -23.59 4.72
2013-09-30 0.39 -19.79 3.49
2013-06-30 0.53 -15.07 3.08
2013-03-31 0.65 -14.61 3.05
2012-12-31 0.81 -15.95 3.12

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Trevena has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Trevena has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Trevena improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Trevena's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Trevena has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

TRVN Health

 How is Trevena's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Trevena's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Trevena is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Trevena's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Trevena's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 4.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Trevena Company Filings, last reported 2 months ago.

NasdaqGS:TRVN Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 46.39 23.18 60.06
2018-12-31 41.53 17.39 61.48
2018-09-30 48.64 20.40 70.04
2018-06-30 38.70 23.39 63.50
2018-03-31 36.32 25.08 61.59
2017-12-31 34.63 28.18 66.10
2017-09-30 46.81 28.10 76.57
2017-06-30 55.61 28.00 84.20
2017-03-31 67.30 27.93 97.91
2016-12-31 78.58 18.33 110.60
2016-09-30 92.69 18.29 119.61
2016-06-30 120.98 18.26 144.51
2016-03-31 138.63 18.23 163.47
2015-12-31 143.13 18.19 172.64
2015-09-30 157.74 1.79 168.97
2015-06-30 92.68 1.76 106.38
2015-03-31 87.09 1.73 100.77
2014-12-31 99.20 1.70 106.90
2014-09-30 64.26 1.79 72.22
2014-06-30 79.09 0.00 81.62
2014-03-31 89.95 0.00 91.34
2013-12-31 39.34 0.00 37.97
2013-09-30 46.72 0.00 47.98
2013-06-30 54.22 0.00 54.77
2013-03-31 1.35 4.87 6.74
2012-12-31 1.35 4.87 6.74
  • Trevena's level of debt (30.9%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 30.9% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Trevena has sufficient cash runway for 2.6 years based on current free cash flow.
  • Trevena has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -28.6% each year.
X
Financial health checks
We assess Trevena's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Trevena has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

TRVN Dividends

 What is Trevena's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Trevena dividends.
If you bought $2,000 of Trevena shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Trevena's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Trevena's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:TRVN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2011 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:TRVN Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Trevena has not reported any payouts.
  • Unable to verify if Trevena's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Trevena's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Trevena has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Trevena's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Trevena afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Trevena has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

TRVN Management

 What is the CEO of Trevena's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Carrie Bourdow
COMPENSATION $1,779,915
AGE 55
TENURE AS CEO 0.7 years
CEO Bio

Ms. Carrie L. Bourdow has been Chief Executive Officer, President and Director at Trevena, Inc., since October 01, 2018. Ms. Bourdow served as an Executive Vice President and Chief Operating Officer of Trevena, Inc., from January 2018 to October 01, 2018. Ms. Bourdow was the Chief Commercial Officer and Senior Vice President of Trevena, Inc. since May 2015 until January 2018. Ms. Bourdow has over 25 years of experience in pharmaceutical sales and marketing. From May 2013 to May 2015, she was Vice President of Marketing, Reimbursement and Operations at Cubist Pharmaceuticals, Inc., where she led launch strategy, marketing, reimbursement and operations for five acute care hospital pharmaceuticals totaling over $1 billion in annual revenues. Prior to joining Cubist in 2013, Ms. Bourdow served for more than 20 years at Merck & Co., Inc., where she held positions of increasing responsibility across several therapeutic areas including anti-infectives, acute heart failure and pain. She has been Director of Nabriva Therapeutics plc since June 23, 2017 and Nabriva Therapeutics GmbH. Ms. Bourdow has a Bachelor of Arts degree from Hendrix College and earned her Masters in Business Administration from Southern Illinois University.

CEO Compensation
  • Carrie's compensation has increased whilst company is loss making.
  • Carrie's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Trevena management team in years:

1
Average Tenure
54.5
Average Age
  • The average tenure for the Trevena management team is less than 2 years, this suggests a new team.
Management Team

Carrie Bourdow

TITLE
President
COMPENSATION
$2M
AGE
55
TENURE
0.7 yrs

Mark Demitrack

TITLE
Senior VP & Chief Medical Officer
COMPENSATION
$866K
AGE
60
TENURE
1.1 yrs

Howard Rockman

TITLE
Scientific Founder

John Hamill

TITLE
Vice President of Finance
AGE
54
TENURE
1 yrs

Erin Clark

TITLE
Senior Director of Corporate Strategy & Investor Relations

Michael Catalano

TITLE
Vice President of Marketing
TENURE
1.3 yrs

Bob Yoder

TITLE
Senior VP & Chief Business Officer
AGE
52
TENURE
0.5 yrs
Board of Directors Tenure

Average tenure and age of the Trevena board of directors in years:

5.9
Average Tenure
61
Average Age
  • The tenure for the Trevena board of directors is about average.
Board of Directors

Lonnie Moulder

TITLE
Independent Chairman
COMPENSATION
$101K
AGE
61
TENURE
6 yrs

Carrie Bourdow

TITLE
President
COMPENSATION
$2M
AGE
55
TENURE
0.7 yrs

Howard Rockman

TITLE
Scientific Founder

Mike Dougherty

TITLE
Independent Director
COMPENSATION
$81K
AGE
60
TENURE
5.8 yrs

Julie McHugh

TITLE
Independent Director
COMPENSATION
$74K
AGE
54
TENURE
4.9 yrs

Barbara Yanni

TITLE
Independent Director
COMPENSATION
$83K
AGE
63
TENURE
4.9 yrs

Max Gowen

TITLE
Director
COMPENSATION
$2M
AGE
60
TENURE
11.6 yrs

Robert Lefkowitz

TITLE
Member of Scientific Advisory Board
AGE
74

John LaMattina

TITLE
Member of the Scientific Advisory Board
AGE
68
TENURE
10.4 yrs

Bob Ruffolo

TITLE
Member of the Scientific Advisory Board
AGE
67
TENURE
10.4 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Trevena insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
04. Jun 19 Buy John Hamill Individual 31. May 19 31. May 19 7,500 $1.16 $8,700
05. Feb 19 Buy Maxine Gowen Individual 01. Feb 19 01. Feb 19 50,000 $1.02 $51,000
04. Feb 19 Buy Leon Moulder Individual 01. Feb 19 01. Feb 19 100,000 $1.02 $102,000
08. Nov 18 Sell Alta Partners LP Company 16. Oct 18 16. Oct 18 -1,000,000 $0.97 $-970,000
X
Management checks
We assess Trevena's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Trevena has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

TRVN News

Simply Wall St News

How Many Trevena, Inc. (NASDAQ:TRVN) Shares Do Institutions Own?

Trevena is not a large company by global standards. … Our analysis of the ownership of the company, below, shows that institutions are noticeable on the share registry. … General Public Ownership The general public, who are mostly retail investors, collectively hold 62% of Trevena shares.

Simply Wall St -

Trevena, Inc. (NASDAQ:TRVN): Will The Growth Last?

The latest earnings announcement Trevena, Inc. … (NASDAQ:TRVN) released in December 2018 … company earnings became less negative compared to the previous year's level

Simply Wall St -

Who Has Been Buying Trevena, Inc. (NASDAQ:TRVN) Shares?

We often see insiders buying up shares in companies that perform well over the long term. … But logic dictates you should pay some attention to whether insiders are buying or selling shares. … Trevena Insider Transactions Over The Last Year.

Simply Wall St -

What Kind Of Investor Owns Most Of Trevena, Inc. (NASDAQ:TRVN)?

Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. … Companies that used to be publicly owned tend to have lower insider ownership. … Taking a look at the our data on the ownership groups (below), it's seems that

Simply Wall St -

Analysts Expect Breakeven For Trevena Inc (NASDAQ:TRVN)

Trevena Inc's (NASDAQ:TRVN):. … The US$118.95m market-cap posted a loss in its most recent financial year of -US$71.86m and a latest trailing-twelve-month loss of -US$60.17m shrinking the gap between loss and breakeven. … See our latest analysis for Trevena

Simply Wall St -

Top Growth Stocks To Buy

NasdaqGS:TRVN Future Profit May 1st 18 Atossa Genetics Inc. … ATOS’s projected future profit growth is a robust 26.19%, with an underlying triple-digit growth from its revenues expected over the upcoming years. … NYSE:TEX Future Profit May 1st 18 For more financially robust companies with high growth potential to enhance your portfolio, explore this interactive list of fast growing companies.

Simply Wall St -

Trevena Inc (NASDAQ:TRVN): When Will It Breakeven?

In this article, I will touch on the expectations for TRVN’s growth and when analysts expect the company to become profitable. … This means that a high growth rate is not unusual, especially if the company is currently in an investment period. … For a more comprehensive look at TRVN, take a look at TRVN’s company page on Simply Wall St.

Simply Wall St -

TRVN Company Info

Description

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of treatment options that target and treat diseases affecting the central nervous system. Its product candidates include Oliceridine injection, a G protein biased mu-opioid receptor (MOR) ligand that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is warranted; TRV250, a G protein biased delta- opioid receptor ligand, which is in Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; TRV027 for the treatment of acute heart failure; and TRV045, a novel S1P modulator for managing chronic pain. The company was founded in 2007 and is headquartered in Chesterbrook, Pennsylvania.

Details
Name: Trevena, Inc.
TRVN
Exchange: NasdaqGS
Founded: 2007
$102,512,538
92,353,638
Website: http://www.trevena.com
Address: Trevena, Inc.
955 Chesterbrook Boulevard,
Suite 110,
Chesterbrook,
Pennsylvania, 19087,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS TRVN Common Stock Nasdaq Global Select US USD 31. Jan 2014
DB 6T4 Common Stock Deutsche Boerse AG DE EUR 31. Jan 2014
Number of employees
Current staff
Staff numbers
29
Trevena employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/19 00:45
End of day share price update: 2019/06/18 00:00
Last estimates confirmation: 2019/05/31
Last earnings filing: 2019/05/10
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.